Glenmark Pharma bags USFDA approval for Metronidazole Vaginal Gel

28 Jan 2022 , 09:55 AM

Glenmark Pharmaceuticals Ltd. has announced that it has received final approval by the United States Food & Drug Administration (U.S. FDA) for Metronidazole Vaginal Gel, 0.75%, the generic version of MetroGel-Vaginal1 Gel, 0.75%, of Bausch Health US, LLC.

Its share opened at Rs 479.20 against its previous closing price of Rs 476.35, and is currently trading at Rs 486.80, up by Rs 10.45 or 2.19%. It touched an intraday high and low of Rs 488.80 and Rs 476 respectively so far in today’s trade.

According to IQVIATM sales data for the 12 months ending November 2021, the MetroGel Vaginal Gel, 0.75% market has made annual sales of approximately $60.4 million.

Glenmark’s current product portfolio includes 172 products authorized for distribution in the U.S. markets, and 46 ANDA’s are pending for approval with the U.S. FDA. Glenmark continues to identify and explore opportunities for external development partnerships to accelerate the growth of its existing supply chain and product portfolio.